A retrospective study of serial CEA determinations in the early detection of recurrent colorectal cancer

Colorectal cancer is the third most commonly diagnosed cancer in males and the second in female, with an estimated 1, 4 million cases and 693,900 deaths occurring in 20121. The aim of this study is to determine the epidemiological characteristics of colorectal cancer in Morocco. This is a descriptive retrospective study of colorectal cancer cases diagnosed and treated at Al Azhar Oncology Center in Rabat between 2005 and 2015. During the period of study, there were 641 cases diagnosed with colorectal cancer; 371 (57, 9%) were men and 270 (42, 1%) were women, there was 54 deaths among which 63% were men and 37% were women. The average age of patients with colorectal cancer was 56 ± 14.6 years whereas the average age of death was 53, 8 ± 13, 7 years. The maximum of frequency for this kind of cancer was between the age of 40 and 59 years old. The study also showed that there was no association between the age and the risk of the death. Despite the limitations of the available data, it is clear that there are several barriers to access to cancer control in developing countries. This includes prevention, early detection, diagnosis and treatment.

Download Full-text

Diagnostic accuracy of C-reactive protein and white blood cell counts in the early detection of inflammatory complications after open resection of colorectal cancer: a retrospective study of 1,187 patients

International Journal of Colorectal Disease ◽

10.1007/s00384-011-1262-0 ◽

2011 ◽

Vol 26 (11) ◽

pp. 1405-1413 ◽

Cited By ~ 45

Author(s):

Rene Warschkow ◽

Ignazio Tarantino ◽

Michael Torzewski ◽

Franziska Näf ◽

Jochen Lange ◽

...

Keyword(s):

Colorectal Cancer ◽

Retrospective Study ◽

Early Detection ◽

Blood Cell ◽

C Reactive Protein ◽

Open Resection ◽

Reactive Protein ◽

Cell Counts ◽

Blood Cell Counts ◽

White Blood Cell Counts

Download Full-text

Intraoperative radiotherapy with low energy photons in recurrent colorectal cancer: a single centre retrospective study

Współczesna Onkologia ◽

10.5114/wo.2016.58500 ◽

2016 ◽

Vol 1 ◽

pp. 52-57

Author(s):

Magdalena Skórzewska ◽

Jerzy Mielko ◽

Andrzej Kurylcio ◽

Jarosław Romanek ◽

Wojciech P. Polkowski

Keyword(s):

Colorectal Cancer ◽

Retrospective Study ◽

Intraoperative Radiotherapy ◽

Low Energy ◽

Recurrent Colorectal Cancer ◽

Single Centre

Download Full-text

Performance comparison of the methylated BCAT1/IKZF1 ctDNA test (COLVERA) with the CEA assay for detection of recurrent colorectal cancer.

Journal of Clinical Oncology ◽

10.1200/jco.2019.37.15_suppl.3589 ◽

2019 ◽

Vol 37 (15_suppl) ◽

pp. 3589-3589 ◽

Cited By ~ 1

Author(s):

Erin L. Symonds ◽

Susanne Kartin Pedersen ◽

David Murray ◽

Susan E Byrne ◽

Paul Hollington ◽

...

Keyword(s):

Colorectal Cancer ◽

Early Detection ◽

Blood Test ◽

Treatment Options ◽

Roc Curves ◽

Circulating Tumor Dna ◽

Performance Comparison ◽

Ct Scans ◽

Recurrent Colorectal Cancer ◽

Current Standard

3589 Background: Early detection of recurrent colorectal cancer (CRC) will improve treatment options, but the current standard blood test of carcinoembryonic-antigen (CEA) has suboptimal sensitivity for recurrence. This study compared performance of a quantitative circulating tumor DNA (ctDNA) assay for methylated BCAT1 and IKZF1 (COLVERA) with that of CEA. Methods: 301 patients were monitored for recurrence after clearance of primary CRC. Blood was collected at scheduled intervals and concentrations of CEA and ctDNA were measured using the LIAISON CEA test (Diasorin) and the COLVERA ctDNA test (Clinical Genomics). Surveillance for recurrent disease was examined using regular CT scans. Sensitivity of each blood test for recurrence was assessed in the sample collected closest to the time of imaging confirming recurrence status. Absence of recurrence was defined as at least two consecutive clear CT scans. Receiver operator characteristic (ROC) analyses were used to determine optimal positivity threshold for Colvera. Results: 131 patients underwent satisfactory assessment for recurrence and had blood testing performed within 12 months of determining recurrence status (61.8% male, mean age 62.6 ±.12.2(SD)y). Of the 47 recurrence cases, 37 (74%) were distant. The areas under the ROC curves were 0.7761 and 0.8188 for CEA and COLVERA, respectively (each p < 0.001). An optimal cut-off of 12.8pg/sample was determined for COLVERA and the standard 5ng/mL cut-off was selected for CEA. COLVERA had a significantly higher sensitivity for detecting recurrence as compared to CEA (68.1% vs 31.9%, p < 0.001) with a similar specificity (97.6% Vs 96.4%, p = 0.6547). A multivariate analysis determined COLVERA to be a predictor of recurrence independent of CEA with positive COLVERA samples being 66.4 times (95%CI 14.0-315.8) more likely to have recurrence confirmed within the study timeframe, whereas CEA was not a significant predictor of recurrence (p = 0.228). Conclusions: These findings indicate that COLVERA, reporting in quantitative mode, is a more sensitive test than CEA. It provides a viable alternative for sensitive and early detection of recurrent CRC. Clinical trial information: 12611000318987.

Download Full-text